Mikhail Leonidovich Zubkin

Mikhail Leonidovich Zubkin

Auto-generated profile, based on publicly available information

Mikhail Leonidovich Zubkin

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Moscow Clinical Research Center «Hospital No. 52»; Branch of the S.M. Kirov Military Medical Academy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
MZM. Zubkin
M. Zubkin
EBE. Balakirev
E. Balakirev
VCV. Chervinko
V. Chervinko
FBF. Baranova
F. Baranova
VZV. Zolotarevsky
V. Zolotarevsky
VNV. Novozhenov
V. Novozhenov
Treatment of chronic hepatitis B in renal transplant recipients remains one of the major problems in clinical nephrology. Lamivudine is considered to be a drug of choice for these patients, however, its efficacy in patients with hepatitis B after renal transplantation (RT) has not been completely proven. Twenty-two RT recipients treated with lamivudine were evaluated. The duration of treatment was 15.6±1.9 months. Fourteen patients (64%) had normalization of aminotransferase (ALT); in 9 of them (41% of the whole group), serum HBV DNA was eliminated. Serum HBeAg was undetectable in 4 out of 15 (27%) previously positive patients. It has been statistically proven that the efficacy of lamivudine therapy correlates with degree of fibrosis and higher histological activity index values. We could not establish any correlation between the outcome of antiviral therapy and patients' age, sex, conditions of contagion (while on dialysis or after RT), time lapsed after the infection had been detected, duration of post-transplant period, type of immunosuppression, HBeAg positivity or negativity, ALT levels, concomitant HCV infection. The efficacy of antiviral HBV therapy is limited by the duration of lamivudine treatment: in 4 out of 5 patients with virologic response, the viremia condition relapsed several weeks after the medication had been stopped. Two patients continued to sustain their biochemical response and 1 patient had ALT levels elevated to above normal, but the value was almost twice as low as initially reported. Liver biopsy was repeated in 4 RT recipients after the end of antiviral therapy; in 3 of them positive morphologic changes were observed.

1 January 2021 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
NFN.F. Frolova
N.F. Frolova
M5Moscow City Hospital N 52
Moscow City Hospital N 52
IKI.G. Kim
I.G. Kim
AUA.I. Ushakova
A.I. Ushakova
SUS.S. Usatiuk
S.S. Usatiuk
NHN.N. Burdenko Main Military Clinical Hospital
N.N. Burdenko Main Military Clinical Hospital

2 July 2018 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MZM. L. Zubkin
M. L. Zubkin
DAD. T. Abdurakhmanov
D. T. Abdurakhmanov
OSO. I. Sagalova
O. I. Sagalova
IBI. G. Bakulin
I. G. Bakulin
MMM. V. Maevskaya
M. V. Maevskaya
VIVladimir Ivashkin
Vladimir Ivashkin
Mixed cryoglobulinemia (MC) and cryoglobulinemic vasculitis (CV) are the most common extrahepatic manifestations of chronic hepatitis C virus (HCV) infection. With novel interferon-free regimens ba...

15 November 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MZM L Zubkin
M L Zubkin
NFN F Frolova
N F Frolova
IKI G Kim
I G Kim
AUA I Ushakova
A I Ushakova
SUS S Usatiuk
S S Usatiuk
EKE V Kryukov
E V Kryukov
Background. Present concepts of the novel coronavirus infection prognosis in haemodialysis (HD) patients are rather controversial. There is little information on therapy efficiency and safety in such patients. We studied COVID-19 course specifics, prognostic factors associated with fatal outcomes, therapy efficiency and its transformation at different stages of the pandemic first year. Materials and methods. Single-centre retrospective uncontrolled study included 653 COVID-19 HD-patients treated at Moscow City Nephrology Centre from April 1 to December 31, 2020. Results. This period mortality rate was 21.0%. Independent predictors of COVID-19 unfavourable outcome in HD patients were pulmonary lesion extension (CT grades 34), high comorbidity index, and mechanical ventilation. Approaches to COVID-19 treatment modified significantly at different periods. Immunomodulatory drugs (monoclonal antibodies to IL-6, corticosteroids) were used largely at later stages. With tocilizumab administration, mortality was 15.1%, tocilizumab together with dexamethasone 13.3%; without them 37.8% (р0,001). Tocilizumab administration in the first 3 days after hospitalization of patients with CT grades 12 was associated with more favourable outcomes: 1 out of 29 died vs 6 out of 20 (tocilizumab administered at later periods); p0.04. There was no significant difference in death frequency in patients with CT grades 34 depending on tocilizumab administration time. Conclusion. COVID-19 in HD patients can manifest in a severe course with unfavourable outcome. It is urgent to identify reliable disease outcome predictors and develop efficient treatment in this population.

1 January 2021 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
MZM.L. Zubkin
M.L. Zubkin
VSV.Yu. Shilo
V.Yu. Shilo
LNL.I. Novikova
L.I. Novikova
OBO.Yu. Borisova
O.Yu. Borisova
IKI.G. Kim
I.G. Kim
SASt. Petersburg S.M. Kirov Military Medical Academy
St. Petersburg S.M. Kirov Military Medical Academy

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
EVE.V. Volodina
E.V. Volodina
NFN.F. Frolova
N.F. Frolova
MLM.A. Lysenko
M.A. Lysenko
IKI.G. Kim
I.G. Kim
AUA.I. Ushakova
A.I. Ushakova
SASt. Petersburg S.M. Kirov Military Medical Academy
St. Petersburg S.M. Kirov Military Medical Academy
Применение нейтрализующих моноклональных антител при SARS-CoV-2-инфекции у больных, получающих лечение гемодиализом